Advances in Type 1 Diabetes Prediction using Islet Autoantibodies: Beyond a Simple Count
In this medfyle
Autoantibodies in T1D.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About the Expert
Raghu G. Mirmira, MD, PhD
University of Chicago, Chicago, IL, USA
Dr. Mirmira is a physician scientist and endocrinologist. He obtained his MD and PhD degrees from the University of Chicago, completed his residency and endocrinology training at the University of California, San Francisco, then held faculty appointments at the University of Virginia, Indiana University, and the University of Chicago (where he is now). He is the Director of the Translational Research Center, an NIH funded investigator, and conducts a research program focused on the role of the islet in diabetes pathogenesis. He serves as Deputy Editor of the Journal of Clinical Endocrinology and Metabolism.
Disclosures: Dr Mirmira serves on the Scientific Advisory Boards for Veralox Therapeutics, HiberCell, and Sigilon Therapeutics.
Acknowledgements
This summary is based upon an article appearing in the journal entitled Endocrine Reviews published by Oxford University Press and was created by GlobalPort. Oxford University Press takes no responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Raghu G. Mirmira, MD, PhD.
Original article:
Michelle So, Cate Speake, Andrea K Steck, Markus Lundgren, Peter G Colman, Jerry P Palmer, Kevan C Herold, Carla J Greenbaum, Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count, Endocrine Reviews, 2021;, bnab013, https://doi.org/10.1210/endrev/bnab013
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of Endocrine Society/Oxford University Press.
References
1. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007;125(2):120–6.
2. James JA, Harley JB. B-cell epitope spreading in autoimmunity. Immunol Rev 1998;164:185–200.
3. Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J Immunol 2010;185(6):3117–25.
4. Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381(7):603–13.
